Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

NIH 6OTHER 5INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 768Breast Neoplasms 731Neoplasm Metastasis 341Colorectal Neoplasms 340Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 237Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 190Lymphoma, Follicular 164Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 120Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

Erlotinib Hydrochloride 2Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Familial ependymoma × Clear all
NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Astellas Pharma Inc

Phase 2 Terminated
4 enrolled 9 charts

Familial ependymoma, Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡